Search

Hendrik Schuurman Phones & Addresses

  • Minneapolis, MN
  • Charlestown, MA

Publications

Us Patents

Combinations Of Immunosuppressive Agents For The Treatment Or Prevention Of Graft Rejections

View page
US Patent:
8435520, May 7, 2013
Filed:
Feb 11, 2011
Appl. No.:
13/025347
Inventors:
Hendrik J. Schuurman - Charlestown MA, US
Emanuele Luigi Maria Cozzi - Padua, IT
Francoise Richard - St. Louis, FR
Guy Taccard - Hegenheim, FR
David James Graham White - Cambridge, GB
Peter John Friend - Oxford, GB
John Wallwork - Cambridge, GB
Paolo Brenner - Neuried, DE
International Classification:
A61K 39/395
A61K 38/13
A61K 47/26
A61K 47/00
US Classification:
4241401, 424 932, 424810, 4242781, 800 17, 514 205, 435 11
Abstract:
A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.

Combinations Of Immunosupressive Agents For The Treatment Or Prevention Of Graft Rejections

View page
US Patent:
20020132764, Sep 19, 2002
Filed:
Nov 7, 2001
Appl. No.:
10/035663
Inventors:
Hendrik Schuurman - Charlestown MA, US
Emanuele Cozzi - Padova, IT
Francoise Richard - St. Louis, FR
Guy Taccard - Hegenheim, FR
David Graham White - London, GB
Peter Friend - Oxford, GB
John Wallwork - Cambridge, GB
Paolo Brenner - Munich, DE
International Classification:
A61K038/13
A61K031/365
A61K031/4745
US Classification:
514/009000, 514/291000, 514/470000
Abstract:
A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.

Combinations Of Immunosupressive Agents For The Treatment Or Prevention Of Graft Rejections

View page
US Patent:
20050277585, Dec 15, 2005
Filed:
Jul 11, 2005
Appl. No.:
11/178573
Inventors:
Hendrik Schuurman - Charlestown MA, US
Emanuele Cozzi - Padova, IT
Francoise Richard - St. Louis, FR
Guy Taccard - Hegenheim, FR
David White - Harston, GB
Peter Friend - Oxford, GB
John Wallwork - Cambridge, GB
Paolo Brenner - Munich, DE
International Classification:
A61K038/13
A61K031/4745
A61K031/337
US Classification:
514011000, 514291000, 514449000
Abstract:
A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.

Combinations Of Immunosupressive Agents For The Treatment Or Prevention Of Graft Rejections

View page
US Patent:
20070060511, Mar 15, 2007
Filed:
Nov 15, 2006
Appl. No.:
11/599814
Inventors:
Hendrik Schuurman - Charlestown MA, US
Emanuele Cozzi - Padova, IT
Francoise Richard - St. Louis, FR
Guy Taccard - Hegenheim, FR
David White - Harston, GB
Peter Friend - Oxford, GB
John Wallwork - Cambridge, GB
Paolo Brenner - Munich, DE
International Classification:
A61K 38/13
A61K 31/4745
A61K 31/365
A61K 9/22
US Classification:
514011000, 514291000, 514469000, 424468000
Abstract:
A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.

Combinations Of Immunosupressive Agents For The Treatment Or Prevention Of Graft Rejections

View page
US Patent:
20080199478, Aug 21, 2008
Filed:
Apr 24, 2008
Appl. No.:
12/109210
Inventors:
Hendrik J. SCHUURMAN - Charlestown MA, US
Emanuele Luigi Cozzi - Padova, IT
Francoise Richard - St. Louis, FR
Guy Taccard - Hegenheim, FR
David James Graham White - Cambridge, GB
Peter John Friend - Oxford, GB
John Wallwork - Cambridge, GB
Paolo Brenner - Munich, DE
International Classification:
A61K 38/13
A61K 39/395
A61P 43/00
US Classification:
4241411, 514 11
Abstract:
A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.
Hendrik J Schuurman from Minneapolis, MN, age ~75 Get Report